Esperion Therapeutics develops medicines for patients with elevated LDL-C. Marketed products include NEXLETOL and NEXLIZET tablets for primary hyperlipidemia treatment. The company also has NILEMDO, an ACL inhibitor, and NUSTENDI, a bempedoic acid and ezetimibe tablet. Esperion has agreements with Daiichi Sankyo, Otsuka Pharmaceutical, and Daiichi Sankyo Europe. Founded in 2008, the company is headquartered in Ann Arbor, Michigan.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 11.3 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 26.0% |
| Net Debt/EBITDA | 2.4 |